Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRVINE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2022 Ethos and Sustainability Report. The report highlights Inari's commitment to its ethos and important corresponding environmental, social and governance (ESG) initiatives. The report can be found on Inari's website here.

Inari Medical Announces the Release of 2022 Ethos and Sustainability Report

IRVINE, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced planned enrollment of the PEERLESS II trial, Inari's third randomized controlled trial (RCT) in venous thromboembolism (VTE). The trial design was presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions.

Inari Medical Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism Patients

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

The consensus price target hints at a 27.7% upside potential for Inari Medical, Inc. (NARI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Inari Medical, Inc. (NARI) Could Surge 27.7%: Read This Before Placing a Bet

Inari Medical, Inc. has several devices for venous thrombectomy like The FlowTriever and ClotTriever devices. Several ongoing clinical trials and increasing quarterly sales have the potential to continue the upside momentum for the stock price.

Inari Medical: Targeting Underpenetrated $5.8 Billion Thromboembolism Market

Inari Medical's (NARI) first-quarter results benefit from significant progress made across all its growth drivers.

Inari Medical (NARI) Q1 Earnings Top, Revenues Rise Y/Y

Inari Medical, Inc. (NASDAQ:NARI ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Caroline Corner - IR Drew Hykes - President and CEO Mitch Hill - CFO Tom Tu - Chief Medical Officer Conference Call Participants Travis Steed - Bank of America Cecilia Furlong - Morgan Stanley Larry Biegelsen - Wells Fargo Adam Maeder - Piper Sandler William Plovanic - Canaccord Marie Thibault - BTIG Richard Newitter - Truist Securities Mike Sarcone - Jeffries Operator Good afternoon, and welcome to the Inari Medical Inc.'s First Quarter 2023 Earnings Call. All participants will be in listen-only mode.

Inari Medical, Inc. (NARI) Q1 2023 Earnings Call Transcript

Inari Medical, Inc. (NARI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.06 per share a year ago.

Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates

IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2023.

Inari Medical Reports First Quarter 2023 Financial Results

IRVINE, Calif., May 02, 2023 (GLOBE NEWSWIRE) --  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the Bank of America 2023 Healthcare Conference on Tuesday, May 9, 2023 at 3:00 p.m. Pacific Time at the Encore Hotel in Las Vegas.

Inari Medical to Present at the Bank of America 2023 Healthcare Conference

IRVINE, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce First Quarter 2023 Financial Results

Inari Medical released positive news regarding its FlowTriever system to prevent pulmonary emboli. The company saw revenue rise by 38% in 2022.

Why Shares of Inari Medical Rose This Week

IRVINE, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced positive results from the FLAME study in high-risk/massive pulmonary embolism (“PE”). The data was presented during the Late-Breaking Clinical and Investigative Horizons session at the 2023 ACC (American College of Cardiology) conference on March 5th by national Principal Investigator (PI) Mitchell Silver, DO, FACC, FVSM, RPVI, an interventional cardiologist and vascular medicine specialist at OhioHealth Riverside Methodist Hospital.

FLAME Study Demonstrates 90% Survival Improvement in High-Risk Pulmonary Embolism with Inari Medical FlowTriever System

Inari Medical has solid top-line growth with expansion in core and new product lines. It continues to focus on reinvestment into future growth, especially in international markets.

Inari Medical: Reinvesting Heavily Into Growing International Markets

Inari Medical's (NARI) fourth-quarter results benefit from significant progress made across all its growth drivers.

Inari Medical (NARI) Q4 Earnings Beat, Revenues Rise Y/Y

Inari Medical, Inc. (NASDAQ:NARI ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Caroline Corner - IR Drew Hykes - President and CEO Mitch Hill - CFO Tom Tu - Chief Medical Officer Conference Call Participants Travis Steed - Bank of America Cecilia Furlong - Morgan Stanley Larry Biegelsen - Wells Fargo Adam Maeder - Piper Sandler Marie Thibault - BTIG Bill Plovanic - Canaccord Mike Sarcone - Jefferies Richard Newitter - Truist Operator Good afternoon, and welcome to the Inari Medical Fourth Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode.

Inari Medical, Inc. (NARI) Q4 2022 Earnings Call Transcript

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 35.29% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Inari Medical, Inc. (NARI) Reports Q4 Loss, Tops Revenue Estimates

IRVINE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2022.

Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results

Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Inari Medical, Inc. (NARI) to Report a Decline in Earnings: What to Look Out for

Inari Medical, Inc. (NARI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Inari Medical, Inc. (NARI) Soars 6.3%: Is Further Upside Left in the Stock?

Amazon

Inmode Ltd

Find out why the investment bankers who follow these stocks think they can soar in the near term.

3 Magnificent Growth Stocks With 38% to 64% Upside Potential, According to Wall Street

IRVINE, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce Fourth Quarter and Full Year 2022 Financial Results

IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 14, 2023.

Inari Medical to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Shockwave Medical

These stocks are all down by at least 42% from their all-time highs despite impressive performances from their underlying businesses.

3 Beaten-Down Growth Stocks That I'm Loading Up On in 2023

Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.

News for Inari Medical Stock (NARI)